ARO-HIF2 shows promise for advanced kidney cancer

A small phase 1b study of a new medicine called ARO-HIF2 has shown promise for the treatment of people with advanced clear cell renal cell carcinoma (RCC). Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF2. This results […]

read more

New class of kidney cancer drugs potentially more effective than sunitinib

A recent pre-clinical study published in the journal Nature¬†shows that a new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer. Hypoxia-inducible factors (HIFs), such as HIF-2, allow the body’s cells to adjust to low-oxygen environments. HIFs are part of a […]

read more
Showing all 2 results